Physician profile
Daniel John Mclaughlin
NPI 1598732646
$16,464.90
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $306 · 2021: $411 · 2022: $2,639.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14,816.49 | 2019-2022 | |
| Endologix LLC | $479.87 | 2020-2021 | |
| Medtronic Vascular, INC. | $271.26 | 2019 | |
| W. L. Gore & Associates, INC. | $270.57 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $264.00 | 2019-2021 | |
| Amgen INC. | $112.63 | 2019-2022 | |
| Cordis US Corp. | $67.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.66 | 2019-2020 | |
| Baxter Healthcare | $34.06 | 2019 | |
| Cook Medical LLC | $25.16 | 2020 | |
| Teleflex LLC | $20.71 | 2019 | |
| Abbott Laboratories | $20.50 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.42 | 2019 | |
| Amarin Pharma, INC. | $14.36 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.21 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.